

# References

# References

1. Ammann, A. J., Addiego, J. E., Wara, D. W., et al., "Polyvalent pneumococcal-Polysaccharide Immunization of Patients With Sick-Cell Anemia and Patients With Splenectomy," *N. Engl. J. Med.* 297:897-900, 1977.
2. Ammann, A. J., Schiffman, G., Addiego, J. E., et al., "Immunization of Immunosuppressed Patients With pneumococcal Polysaccharide Vaccine," *Rev. Infect. Dis.* 3 Suppl:160-167, March-April 1981.
3. Ammann, A. J., Schiffman, G., and Austrian, R., "The Antibody Responses to pneumococcal Capsular Polysaccharides in Aged Individuals," *Proc. Soc. Exptl. Biol. & Med.* 164:312-6, 1980.
4. Austrian, R., University of Pennsylvania School of Medicine, personal communication, February 1984.
5. Austrian, R., "In Assessment of the Pneumococcal Polysaccharide Vaccine," E. H. Kass (ed.), *Rev. Meet. Dis.* 3 Suppl:S1-197, March-April 1981.
6. Austrian, R., "Surveillance of pneumococcal Infection for Field Trials of Polyvalent Pneumococcal Vaccines," National Institutes of Health, Report DAB-VOP-12-84:1-84, Bethesda, Md., 1980.
7. Barrett, D. J., and Ammann, A. J., "Pneumococcal Vaccine in Sick Cell Disease: IgG and IgM Antibody Response," *Rev. Infect. Dis.* 3 Suppl:S179-182, March-April 1981.
8. Bentley, D. W., Ha, K., Mamot, K., et al., "Pneumococcal Vaccine in the Institutionalized Elderly: Design of a Nonrandomized Trial and Preliminary Results," *Rev. Infect. Dis.* 3 Suppl:S71-81, March-April 1981.
9. Bentley, D. W., Insel, R. A., and Schiffman, G., "Impaired Antibody Response to pneumococcal Vaccine in the Institutionalized Elderly," *Program and Abstracts*, Abstract No. 242, InterScience Conference on Antimicrobial Agents and Chemotherapy, Miami Beach, Fla., Oct. 4-6, 1982.
10. Bolan, G., Centers for Disease Control, presentation to the Immunization Practices Advisory Committee, Atlanta, Ga., Feb. 8, 1984.
11. Boyer, K. M., Theeravuthichai, J., Vogel, L. C., et al., "Antibody Response to Group B Streptococcus Type III and AB Blood Group Antigens Induced by pneumococcal Vaccine," *J. Pediatr.* 98:374-8, 1981.
12. Broome C. V., Centers for Disease Control, Atlanta, Ga., personal communication, Jan. 20, 1984.
13. Broome, C. V., "Efficacy of pneumococcal Polysaccharides Vaccines," *Rev. Infect. Dis.* 3 Suppl: 582-96, March-April 1981.
14. Broome, C. V., and Facklam, R. R., "Epidemiology of Clinically Significant Isolates of Streptococcus Pneumonia in the United States," *Rev. Infect. Dis.* 3(2):277-280, March-April 1981.
15. Broome, C. V., Facklam, R. R., Allen, J. R., et al., "Epidemiology of pneumococcal Serotypes in The United States 1978-1979," *J. Infect. Dis.* 141: 119-123, 1980.
16. Broome, C. V., Facklam, R. R., and Fraser, D. W., "pneumococcal Disease After pneumococcal Vaccination," *N. Engl. J. Med.* 303:549-552, Sept. 4, 1980.
17. Chalkley, J., Travelers Insurance Co., Richmond, Va., personal communication, Feb. 22, 1984.
18. Cosio, F. G., Giebink, G. S., Le, C. T., et al., "pneumococcal Vaccination in Patients With Chronic Renal Disease and Renal Allograft Recipients," *Kidney Int.* 20(2):254-8, 1981.
19. Davis, A. L., Aranda, C., Christianson, L., et al., "pneumococcal Antibodies in Patients With Chronic Obstructive Pulmonary Disease and Their Response to pneumococcal Capsular Polysaccharides: Preliminary Results," *Rev. Infect. Dis.* 3 Suppl:S183, March-April 1981.
20. Dull, H. B., "pneumococcal Immunization: Policy Development and Implementation From the ACIP Perspective," *Infection Control* 3(4):316-318, July-August 1982.
21. Eddins, D., Centers for Disease Control, U.S. Department of Health and Human Services, Atlanta, Ga., personal communication, February 1984.
22. Fedson, D. S., "Improving the Use of Pneumococcal Vaccine Through a Strategy of Hospital-Based Immunization: Epidemiologic Rationale and Implications," paper prepared for the Immunization Practices Advisory Committee, Public Health Service, Charlottesville, Va., Feb. 8, 1984.
23. Fedson, D. S., University of Virginia Medical Center, Charlottesville, Va., personal communication, Feb. 1, 1984.
24. Filice, G. A., Darby, C. P., and Fraser, D. W., "pneumococcal Bacteremia in Charleston County, S.C.," *Am. J. Epidemiol.* 112:828-835, 1980.
25. Fey, H. M., Wentworth, B., Kenny, G. E., et al., "pneumococcal Isolations From Patients With Pneumonia and Control Subjects in a Prepaid Medical Care Group," *A. Rev. Resp. Dis.* 3:595-603, 1975.
26. Friedman, R., Pharmaceutical Manufacturers As-

- sociation, Washington, D. C., personal communication, Feb. 6, 1984.
27. Gibson, R. M., Department of Health, Education, and Welfare, Washington, D. C., personal communication, December 1978.
28. Giebink, G. S., Le, C. T., Cosio, F. G., et al., "Serum Antibody Responses of High-Risk Children and Adults to Vaccination With Capsular Polysaccharides of *Streptococcus Pneumoniae*," *Rev. Infect. Dis.* 3 Suppl:S168-78, March-April 1981.
29. Heuschele, F., Bureau of Program Operations, Health Care Financing Administration, Baltimore, Md., personal communication, Feb. 29, 1984.
30. Hill, J., National Institute for Allergy and Infectious Disease, Bethesda, Md., personal communication, Jan. 6, 1984.
31. Hilleman, M. R., Carlson, A. J., McLean, A. A., et al., "Streptococcus Pneumonia Polysaccharide Vaccine: Age and Dose Responses, Safety, Persistence of Antibody, Revaccination, and Simultaneous Administration of pneumococcal and Influenza Vaccines," *Rev. Infect. Dis.* 3 Suppl:S31-42, March-April 1981.
32. Hinman, A. R., Centers for Disease Control, U.S. Department of Health and Human Services, Atlanta, Ga., personal communication, Feb. 1, 1984.
33. Hinman, A. R., and Jordan, W. S., Jr. "Progress Toward Achieving the 1990 Immunization Objectives," *Pub. Health Rep.* 98:436-443, September-October 1983.
34. Hosea, S. W., Burch, C. G., Brown, E. J., et al., "Impaired Immune Response of Splenectomized Patients to Polyvalent pneumococcal Vaccine," *Lancet* 1(8224):804-7, 1981.
35. Hoyer, T., Bureau of Eligibility, Reimbursement, and Coverage, Health Care Financing Administration, Baltimore, Md., personal communication, Feb. 29, 1984.
36. IMS America, Ltd., Rockville, Md., unpublished data, February 1984.
37. "Influenza Vaccines 1982-1983," *Morbid. Mortal. Weekly Rep.* 31: 349-353, 1982.
38. Jackman, P., Bureau of Labor Statistics, U.S. Department of Commerce, Washington, D. C., personal communication, Feb. 6, 1984.
39. Jarrett, M. P., Schiffman, G., Barland, P., et al., "Impaired Response to pneumococcal Vaccine in Systemic Lupus Erythematosus," *Arthritis Rheum.* 23(11):1287-93, 1980.
40. Jones, J. K., and Kennedy, D. L., "Data Sources and Methods for Ascertaining Human Response to Drugs," presented at an FDA, NIH, and EPA symposium, Bethesda, Md., fall 1982.
41. Kavet, J., Department of Health and Human Services, Office of the Assistant Secretary for Health, Washington, D. C., personal communication, Feb. 15, 1984.
42. Karsh, J., Pavlidis, N., Schiffman, G., et al., "Immunization of Patients With Sjogren's Syndrome With pneumococcal Polysaccharide Vaccine: A Randomized Trial," *Arthritis Rheum.* 23(11):1294-8, 1980.
43. Kelton, J. G., "Vaccination-Associated Relapse of Immune Thrombocytopenia," *J. A.M.A.* 245(4): 369-70, 1981.
44. Klein, D., Bacterial Vaccine Program Officer, National Institute on Allergy and Infectious Diseases, National Institute of Health, Bethesda, Md., personal communication, January 1984.
45. Landesman, S. H., and Schiffman, G., "Assessment of the Antibody Responses to Pneumococcal Vaccine in High-Risk Populations," *Rev. Infect. Dis.* 3 Suppl:S184-97, March-April 1981.
46. Lederle Laboratories, Pearl River, N. J., unpublished data, January 1984.
47. Lederman, M. M., Schiffman, G., and Rodman, H. M., "pneumococcal Immunization in Adult Diabetics," *Diabetes* 30:119-121, 1981.
48. Lee, S. S., Michael Reese Hospital and Medical Center, Chicago, Ill., personal communication, January 1984.
49. Linnemann, C. C., First, M. R., and Schiffman, G., "Response to pneumococcal Vaccine in Renal Transplant and Hemodialysis Patients," *Arch. Intern. Med.* 141(12):1637-40, 1981.
50. MacFarlane, J. T., Finch, R. G., Ward, M. J., et al., "Hospital Study of Adult Community-Acquired Pneumonia," *Lancet* 2:255-58, 1982.
51. McCue, J. D., "Adverse Reaction to Simultaneous Influenza and pneumococcal Vaccination," *J. Fam. Pract.* 13(2):175-7, 1981.
52. Merck Sharpe & Dohme, West Point, N. Y., unpublished data, February 1984.
53. Mufson, M. A., Krause, H. E., and Schiffman, G., "Long-Term Persistence of Antibody Following Immunization With pneumococcal Polysaccharide Vaccine," *Proc. Soc. Exptl. & Med.* 173:270-275, 1983.
54. Mufson, M. A., Oley, G., and Hughey, D., "Pneumococcal Disease in a Medium-Sized Community in the United States," *J. A.M.A.* 248:1486-89, 1982.
55. Patriarca, P. A., Schlech, W. F., Hinman, A. R., Corm, J. H., and Gunn, W. J., "pneumococcal Vaccination Practices Among Private Physicians," *Pub. Health Rep.* 97(5):406-408, September-October 1982.
56. Patrick, K. M., and Woolley, F. R., "A Cost-Ben-

- efit Analysis of Immunization for pneumococcal Pneumonia," *J. A.M.A.* 245(5):473-7, 1981.
57. Phelps, C., The Rand Corp., Santa Monica, Calif., January 1984.
  58. "Recommendation of the Immunization Practices Advisory Committee (ACPI): pneumococcal Polysaccharide Vaccine," *Morb. Mortal. Weekly Rep.* 30:410-419, 1981.
  59. "Recommendation of the Public Health Service Advisory Committee on Immunization Practices: pneumococcal Polysaccharide Vaccine," *Morb. Mortal. Weekly Rep.* 27(4)25-31, Jan. 27, 1978.
  60. Riddiough, M. A., "Federal Policy for Pneumococcal Immunization and Its Implementation in the Medicare Program," *Infection Control* 3:309-315, 1982.
  61. Riddiough, M. A., Sisk, J. E., and Bell, J. C., "Influenza Vaccination: Cost Effectiveness and Public Policy," *J. A.M.A.* 249(23):3189-3195, June 17, 1983.
  62. Robbins, J. B., Austrian, R., Lee, C. J., et al., "Considerations for Formulating the Second-Generation pneumococcal Capsular Polysaccharide Vaccine With Emphasis on the Cross-Reactive Types Within Groups," *J. Infect. Dis.* 148(6):1136-1159, 1983.
  63. Ryser, P., IMS America, Ltd., Rockville, Md., personal communication, January 1984.
  64. Schmid, G. P., Smith, R. P., Baltch, A. L., et al., "Antibody Response to pneumococcal Vaccine in Patients With Multiple Myeloma," *J. Infect. Dis.* 143(4):590-7, 1981.
  65. Schneider, E. L., "Infectious Diseases in the Elderly," *Ann. Intern. Med.* 98:395-400, 1983.
  66. Schoenbaum, S., Harvard Community Health Plan, Boston, Mass., Feb. 8, 1984.
  67. Schwartz, J. S., "pneumococcal Vaccine: Clinical Efficacy and Effectiveness," *Ann. Intern. Med.* 96(2):208-20, 1982.
  68. Scitovsky, A. A., "Changes in the Use of Ancillary Services for 'Common' Illness," in *Medical Technology: The Culprit Behind Health Care Costs?* S. H. Altman and R. Blendon (eds.), DHEW publication No. 79-3216 (Hyattsville, Md.: U.S. Department of Health, Education, and Welfare, 1979).
  69. Shapiro, E. D., Yale School of Medicine, presented to Immunization Practices Advisory Committee, Atlanta, Ga., Feb. 8, 1984.
  70. Shinefield, H. R., Kaiser Permanente Medical Care Program, San Francisco, Calif., personal communication, Jan. 10, 1984.
  71. Siber, G. R., Ambrosino, D. M., and Gorgone, B. C., "Blood-Group-A-Like Substance in a Preparation of pneumococcal Vaccine," *Ann. Intern. Med.* 96:580-6, 1982.
  72. Siber, G. R., Weitzman, S. A., and Aisenberg, A. C., "Antibody Response of Patients With Hodgkin's Disease to Protein and Polysaccharide Antigens," *Rev. Infect. Dis.* 3 Suppl:S144-S159, 1981.
  73. Simberkoff, M. S., Study Director, Veterans Administration Medical Center, New York, N. Y., personal communication, Jan. 10, 1984.
  74. Stollerman, G., School of Medicine, Boston University, Boston, Mass., Feb. 9, 1984.
  75. Sumpter, J., Associate Manager, Medicare, Travelers Insurance Co., Richmond, Va., personal communication, January 1984.
  76. Swartz, E., Health Care Financing Administration, Bureau of Program Operations, Baltimore, Md., personal communication, Jan. 4, 1984.
  77. U.S. Congress, Office of Technology Assessment, *A Review of Selected Federal Vaccines and Immunization Policies* (Washington, D. C.: U.S. Government Printing Office, 1979).
  78. U.S. Congress, Office of Technology Assessment, *Cost Effectiveness of Influenza Vaccination* (Washington, D. C.: U.S. Government Printing office, 1981).
  79. U.S. Congress, Office of Technology Assessment, *Medical Technology Under Proposals to Increase Competition in Health Care* (Washington, D. C.: U.S. Government Printing Office, 1982).
  80. U.S. Department of Commerce, Bureau of the Census, *Statistical Abstract of the United States: 1982-83* (Washington, D. C.: U.S. Government Printing Office, 1982).
  81. U.S. Department of Health and Human Services, Food and Drug Administration, Office of Biologics, "Summary for Basis of Approval," Bethesda, Md., July 15, 1983.
  82. U.S. Department of Health and Human Services, Food and Drug Administration, Office of Biologics, "Summary for Basis of Approval," Bethesda, Md., June 30, 1983.
  83. U.S. Department of Health and Human Services, Health Care Financing Administration, *Medicare: Summary of Use and Reimbursement by Person, 1978*, HCFA publication No. 03116, Baltimore, Md., August 1981.
  84. U.S. Department of Health and Human Services, National Institute on Aging, National Institute of Allergy and Infectious Diseases, "Announcement: Research on Infectious Diseases in the Elderly," vol. 11, No. 12, Bethesda, Md., Nov. 5, 1982.
  85. U.S. Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Office of Research

- Reporting and Public Response, "Infectious Disease Research: pneumococcal Infections, " Bethesda, Md., October 1977.
86. U.S. Department of Health and Human Services, Public Health Service, "Immunization Priority Objectives Implementation Plan, " *Pub. Health Rep.* 98:(5), Suppl.:44-49, September-October 1983.
  87. U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control, Division of Immunization, unpublished data, "U.S. Immunization Survey: 1982," Atlanta, Ga., January 1984.
  88. U.S. Department of Health, Education, and Welfare, Public Health Service, Centers for Disease Control, Bureau of State Services, Immunization Services, "U.S. Immunization Survey: 1978," Atlanta, Ga., July 1979.
  89. Warner, K., American Public Health Association, Dallas, Tex., Nov. 15, 1983.
  90. Weinstein, M. C., and Stason, W. B., *Hypertension: A Policy Perspective* (Cambridge, Mass.: Harvard University Press, 1976).
  91. Willems, J. S., Sanders, C. R., Riddiough, M. A., and Bell, J. C., "Cost Effectiveness of Vaccination Against pneumococcal Pneumonia, " *N. Engl. J. Med.* 303(10):553-559, Sept. 4, 1980.
  92. World Health Organization, "Proposed Requirements for pneumococcal Polysaccharide Vaccine, " April 1980.
  93. Young, D., Health Care Financing Administration, Bureau of Eligibility and Coverage, Baltimore, Md., personal communication, Dec. 29, 1983.
  94. Zavoina, W. J., Program Analyst, Bureau of Program Operations, Health Care Financing Administration, Baltimore, Md., January 1984.